Publications

Back to Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/ard-2022-222487.

Ugarte-Gil, et al. examine, for the first time, the independent impact of remission off-treatment and on-treatment, LDA-TC and mLLDAS on damage accrual after adjustment for possible confounders, and find that achieving any of these possible targets is associated with a lower probability of damage accrual.

Keywords:


LinkedIn